600276 Jiangsu Hengrui Pharmaceuticals Co.,Ltd.
Closed 06-26 15:00:00
48.67
-1.37
-2.74%
High50.73Low48.62Vol74.96M
Open50.46D1 Closing50.04Amplitude4.22%
Mkt Cap323.02BTradable Cap310.47BTotal Shares6.64B
T/O3.71BT/O Rate1.18%Tradable Shares6.38B
P/B5.08ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Hengrui Pharma Gets Nod to Trial HRS-4508 Tablets As Advanced Tumor Treatment; Shares Down 4%
MT Newswires Live  ·  11:10
Hengrui Pharma Gets Nod to Trial HRS-4508 Tablets As Advanced Tumor Treatment; Shares Down 4%
Hengrui Pharma's Adebrelimab Injection Gains Approval for Additional NSCLC Perioperative Indication
Stock News  ·  06-25 20:59
Hengrui Pharma's Adebrelimab Injection Gains Approval for Additional NSCLC Perioperative Indication
Jiangsu Hengrui Pharmaceuticals - Subsidiary Received Notification from Nmpa Approving New Indication for Adebrelimab Injection
THOMSON REUTERS  ·  06-25 20:48
Jiangsu Hengrui Pharmaceuticals - Subsidiary Received Notification from Nmpa Approving New Indication for Adebrelimab Injection
Jiangsu Hengrui Pharmaceuticals Says Unit Receives China Nmpa Approval for Cyclosporine Eye Drops (iv)
THOMSON REUTERS  ·  06-25 18:48
Jiangsu Hengrui Pharmaceuticals Says Unit Receives China Nmpa Approval for Cyclosporine Eye Drops (iv)
Hengrui Pharma Withdraws Registration Application for Emaxitinib Ointment
Stock News  ·  06-23
Hengrui Pharma Withdraws Registration Application for Emaxitinib Ointment
Hengrui Pharma Says It Withdraws Registration Application for Ivarmacitinib Ointment
THOMSON REUTERS  ·  06-23
Hengrui Pharma Says It Withdraws Registration Application for Ivarmacitinib Ointment
BRIEF-Hengrui Pharma Withdraws Registration Application For Ivarmacitinib Ointment
Reuters  ·  06-23
BRIEF-Hengrui Pharma Withdraws Registration Application For Ivarmacitinib Ointment
Hengrui Pharma's Novel Drug Application for Rezvilutamide Accepted by European Regulator
Stock News  ·  06-22
Hengrui Pharma's Novel Drug Application for Rezvilutamide Accepted by European Regulator
Schroders Increases Stake in Hengrui Pharma by 948,800 Shares at HK$54.54 Per Share
Stock News  ·  06-17
Schroders Increases Stake in Hengrui Pharma by 948,800 Shares at HK$54.54 Per Share
Hengrui Pharma Executes Share Buyback on June 17
Stock News  ·  06-17
Hengrui Pharma Executes Share Buyback on June 17
China approves Hengrui’s dalpiciclib for adjuvant treatment of high-risk early HR+/HER2- breast cancer
Reuters  ·  06-17
China approves Hengrui’s dalpiciclib for adjuvant treatment of high-risk early HR+/HER2- breast cancer
China Greenlights Clinical Trials for Two Hengrui Pharma Drugs, Approves Another Indication for Breast Cancer Drug
MT Newswires Live  ·  06-17
China Greenlights Clinical Trials for Two Hengrui Pharma Drugs, Approves Another Indication for Breast Cancer Drug
Jiangsu Hengrui Pharmaceuticals - Received Notice From Nmpa New Indication for Dalpiciclib Isethionate Tablets, Cdk4/6 Inhibitor Approved
THOMSON REUTERS  ·  06-16
Jiangsu Hengrui Pharmaceuticals - Received Notice From Nmpa New Indication for Dalpiciclib Isethionate Tablets, Cdk4/6 Inhibitor Approved
HENGRUI PHARMA Receives Clinical Trial Approval for SHR-6914 Injection
Stock News  ·  06-16
HENGRUI PHARMA Receives Clinical Trial Approval for SHR-6914 Injection
Hengrui Medicine issues 37 NSFC private-sector joint fund grant calls worth 77 million yuan
Reuters  ·  06-16
Hengrui Medicine issues 37 NSFC private-sector joint fund grant calls worth 77 million yuan
Hengrui's Dual-Target Fusion Protein SHR-2173 Shows Promising Phase I Results for Lupus at EULAR 2026
Deep News  ·  06-11
Hengrui's Dual-Target Fusion Protein SHR-2173 Shows Promising Phase I Results for Lupus at EULAR 2026
Hengrui Pharma Executes Share Buyback on June 10
Stock News  ·  06-10
Hengrui Pharma Executes Share Buyback on June 10
Jiangsu Hengrui files HKEX next-day disclosure return on share repurchase for treasury shares
Reuters  ·  06-10
Jiangsu Hengrui files HKEX next-day disclosure return on share repurchase for treasury shares
Hengrui Pharma and Subsidiaries Secure Clinical Trial Approvals for Three Drug Candidates
Stock News  ·  06-09
Hengrui Pharma and Subsidiaries Secure Clinical Trial Approvals for Three Drug Candidates
HENGRUI PHARMA Repurchases 70,000 A-Shares for RMB 3.1936 Million on June 9
Stock News  ·  06-09
HENGRUI PHARMA Repurchases 70,000 A-Shares for RMB 3.1936 Million on June 9

Introduction

Company Name.
江苏恒瑞医药股份有限公司
Industry:
医药制造业
Listing Date:
2000-10-18
Main Business:
　　江苏恒瑞医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是马来酸吡咯替尼片、注射用卡瑞利珠单抗、瑞维鲁胺片、海曲泊帕乙醇酰胺片、羟乙磺酸达尔西利片、碘佛醇注射液。自2019年起，公司连续七年跻身美国《制药经理人》(PharmExec)杂志评选的全球制药企业50强榜单。
Issue price:
11.98